PYC Therapeutics

31 October 2024

PRESENTATION OF RP11 SINGLE DOSE DATA AT RANZCO

- **PYC is developing the first drug candidate (VP-001) for a blinding eye disease of childhood called Retinitis Pigmentosa type 11 (RP11)**
- **RP11 patients enrolled in PYC's ongoing Phase 1/2 studies have improved vision following treatment with VP-001[1]**
- **Associate Professor Fred Chen of the Lions Eye Institute will present data on the safety/tolerability and efficacy profile of VP-001 in patients who have received a single dose of the drug candidate at the Royal Australian and New Zealand College of Ophthalmologists (RANZCO) meeting to be held in Adelaide between November 1 and 4**

PERTH, Australia and SAN FRANCISCO, California – 31 October 2024

PYC Therapeutics (ASX:PYC) is a clinical-stage biotechnology company creating first in class precision therapies for patients with genetic diseases and no treatment options available. One of the Company's assets[2] is a drug candidate (known as VP-001) that addresses the underlying cause of a blinding eye disease called Retinitis Pigmentosa type 11 (RP11).

PYC today announces that data from the single dose study of VP-001 in patients with RP11 will be presented by Associate Professor Fred Chen of the Lions Eye Institute at the RANZCO meeting to be held between 1 and 4 November 2024. A copy of the poster presentation to be made by A/Prof Chen will be made available on the Posters and Publications section of the Company's website following the presentation.

PYC's RP11 Program Overview

- Retinitis Pigmentosa type 11 (RP11) is a blinding disease of childhood affecting 1 in every 100,000 people
- RP11 is caused by a mutation in 1 copy of the *PRPF31* gene leading to a protein insufficiency in photoreceptor and Retinal Pigment Epithelial (RPE) cells
- VP-001 increases expression of *PRPF31* back to wild-type ('unaffected') levels in RP11 patient-derived retinal organoids and iPSC-RPE[3] (RPE cells grown from patients after turning a skin sample from the patient into an induced Pluripotent Stem Cell (iPSC) and then into the specific cell type in the eye that is affected by

[1] See ASX announcements of 5 August, 12 August and 22 October 2024
[2] PYC owns 96.2% of VP-001 with the remaining 3.8% owned by the Lions Eye Institute
[3] See ASX Announcement of 7 October 2020

the disease to provide a human model of the disease-affected eye outside of a human)

- VP-001 is the first drug candidate to have progressed into human trials for RP11 and has been granted fast track and orphan drug status by the FDA[4]

- RP11 represents an estimated >$1 billion p.a. addressable market[5]

About PYC Therapeutics

PYC Therapeutics (ASX: PYC) is a clinical-stage biotechnology company creating a new generation of RNA therapies to change the lives of patients with genetic diseases. The Company utilises its proprietary drug delivery platform to enhance the potency of precision medicines within the rapidly growing RNA therapeutic class. PYC's drug development programs target monogenic diseases – **the indications with the highest likelihood of success in clinical development**[6].

The Company has multiple ongoing clinical trials and is set to deliver human efficacy data for first-in-class drugs with disease modifying potential across multiple indications within the coming 12 months. The Company's existing drug development pipeline includes four programs addressing indications affecting 1 in every 1,000 people. PYC continues to conduct drug discovery activities to scale its platform technology into additional diseases of the eye, central nervous system, kidney and beyond.

For more information, visit pyctx.com, or follow us on LinkedIn and X.

Forward looking statements

Any forward-looking statements in this ASX announcement have been prepared on the basis of a number of assumptions which may prove incorrect and the current intentions, plans, expectations, and beliefs about future events are subject to risks, uncertainties and other factors, many of which are outside the Company's control. Important factors that could cause actual results to differ materially from assumptions or expectations expressed or implied in this ASX announcement include known and unknown risks. Because actual results could differ materially to assumptions made and the Company's current intentions, plans, expectations, and beliefs about the future, you are urged to view all forward-looking statements contained in this ASX announcement with caution. The Company undertakes no obligation to publicly update any forward-looking statement whether as a result of new information, future events or otherwise.

This ASX announcement should not be relied on as a recommendation or forecast by the Company. Nothing in this ASX announcement should be construed as either an offer to sell or a solicitation of an offer to buy or sell shares in any jurisdiction.

This ASX announcement was approved and authorised for release by the CEO of PYC Therapeutics Limited

[4] FDA: US Food and Drug Administration. Refer to ASX announcements of 2 August 2023 and 21 October 2024
[5] Market valuation informed by patient prevalence (See: Sullivan L, et al. Genomic rearrangements of the PRPF31 gene account for 2.5% of autosomal dominant retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2006;47(10):4579-88) and median orphan drug pricing of $150k p.a. (Evaluate Pharma. Orphan Drug Report. 2019)
[6] Advancing Human Genetics Research and Drug Discovery through Exome Sequencing of the UK Biobank https://doi.org/10.1101/2020.11.02.20222232

CONTACTS:

INVESTORS and MEDIA
info@pyctx.com